A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation.
作者信息
Garshick Michael S, Drenkova Kamelia, Barrett Tessa J, Schlamp Florencia, Fisher Edward A, Katz Stuart, Jelic Sanja, Neimann Andrea L, Scher Jose U, Krueger James, Berger Jeffrey S
机构信息
Center for the Prevention of Cardiovascular Disease, Department of Medicine, NYU Langone Health, New York, New York, USA; Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health, New York, New York, USA; Cardiovascular Research Center, NYU Langone Health, New York, New York, USA.
Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health, New York, New York, USA; Cardiovascular Research Center, NYU Langone Health, New York, New York, USA.
出版信息
J Invest Dermatol. 2022 Jun;142(6):1749-1752.e4. doi: 10.1016/j.jid.2021.07.190. Epub 2021 Nov 19.
Abstract
摘要
相似文献
1
A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation.一项关于银屑病降脂治疗以减轻血管内皮炎症的随机开放标签临床试验。
J Invest Dermatol. 2022 Jun;142(6):1749-1752.e4. doi: 10.1016/j.jid.2021.07.190. Epub 2021 Nov 19.
2
The effect of statins on severity of psoriasis: A systematic review.他汀类药物对银屑病严重程度的影响：一项系统评价。
Indian J Dermatol Venereol Leprol. 2017 Mar-Apr;83(2):154-161. doi: 10.4103/0378-6323.188655.
3
Cumulative in-trial and post-trial effects of blood pressure and lipid lowering: systematic review and meta-analysis.血压和血脂降低的试验期间及试验后累积效应：系统评价与荟萃分析。
J Hypertens. 2017 May;35(5):905-913. doi: 10.1097/HJH.0000000000001233.
4
Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.系统评价和网络荟萃分析：依洛尤单抗与其他疗法在治疗高血脂症患者血脂水平方面的疗效比较。
J Am Heart Assoc. 2017 Oct 2;6(10):e005367. doi: 10.1161/JAHA.116.005367.
5
Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial.昂戈瑞西单抗在中国他汀不耐受的原发性高胆固醇血症或混合性血脂异常患者中的疗效和安全性：一项随机、安慰剂对照的3期试验。
Atherosclerosis. 2025 Jun 16;407:120408. doi: 10.1016/j.atherosclerosis.2025.120408.
6
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.PCSK9 抑制剂和依折麦布降低心血管事件风险的临床实践指南：基于风险分层的推荐意见。
BMJ. 2022 May 4;377:e069066. doi: 10.1136/bmj-2021-069066.
7
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.利洛昔班治疗或有心血管疾病风险患者的疗效和安全性：一项随机临床试验。
JAMA Cardiol. 2024 Sep 1;9(9):800-807. doi: 10.1001/jamacardio.2024.1659.
8
Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials.比较 7 种他汀类药物在血脂异常、心血管疾病或糖尿病患者中的降脂/增脂疗效：50 项随机对照试验的系统评价和网络荟萃分析。
Cardiovasc Ther. 2020 Apr 23;2020:3987065. doi: 10.1155/2020/3987065. eCollection 2020.
9
10
Efficacy and safety of statins and exercise combination therapy compared to statin monotherapy in patients with dyslipidaemia: A systematic review and meta-analysis.他汀类药物与运动联合治疗与他汀类药物单药治疗相比在血脂异常患者中的疗效和安全性：一项系统评价和荟萃分析。
Eur J Prev Cardiol. 2017 Jun;24(9):907-916. doi: 10.1177/2047487317691874. Epub 2017 Feb 13.
引用本文的文献
1
Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network.银屑病和银屑病关节炎临床多中心推进网络为皮肤科医生、风湿病学家和初级保健医生提供的关于银屑病和银屑病关节炎患者心血管风险评估的实用建议
J Psoriasis Psoriatic Arthritis. 2025 May 28:24755303251337020. doi: 10.1177/24755303251337020.
2
Cardiovascular disease risk in psoriatic disease: mechanisms and implications for clinical practice.银屑病性疾病中的心血管疾病风险：机制及对临床实践的意义
Curr Opin Rheumatol. 2025 Jul 1;37(4):261-268. doi: 10.1097/BOR.0000000000001092. Epub 2025 May 13.
3
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults.成人特殊人群使用他汀类药物预防心血管疾病
Curr Atheroscler Rep. 2025 May 1;27(1):54. doi: 10.1007/s11883-025-01298-8.
4
Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review.心血管问题的考虑因素及对银屑病治疗的影响：最新综述。
Vasc Health Risk Manag. 2024 May 10;20:215-229. doi: 10.2147/VHRM.S464471. eCollection 2024.
5
Update on Obesity in Psoriasis Patients.银屑病患者肥胖问题的最新进展
Life (Basel). 2023 Sep 22;13(10):1947. doi: 10.3390/life13101947.
6
Disease modification in inflammatory skin disorders: opportunities and challenges.炎症性皮肤疾病的疾病修饰：机遇与挑战。
Nat Rev Drug Discov. 2023 Aug;22(8):662-680. doi: 10.1038/s41573-023-00735-0. Epub 2023 Jul 13.
7
Effects of Hypolipidemic Drugs on Psoriasis.降血脂药物对银屑病的影响。
Metabolites. 2023 Mar 29;13(4):493. doi: 10.3390/metabo13040493.
8
An inflammatory transcriptomic signature in psoriasis associates with future cardiovascular events.银屑病中的炎症转录组特征与未来心血管事件相关。
J Eur Acad Dermatol Venereol. 2023 Jul;37(7):1361-1365. doi: 10.1111/jdv.19049. Epub 2023 Mar 22.
9
Biologics for Reducing Cardiovascular Risk in Psoriasis Patients.用于降低银屑病患者心血管风险的生物制剂。
J Clin Med. 2023 Feb 1;12(3):1162. doi: 10.3390/jcm12031162.
10
Statin therapy upregulates arachidonic acid status via enhanced endogenous synthesis in patients with plaque psoriasis.他汀类药物治疗可通过增强斑块状银屑病患者内源性合成来上调花生四烯酸状态。
Prostaglandins Leukot Essent Fatty Acids. 2022 May;180:102428. doi: 10.1016/j.plefa.2022.102428. Epub 2022 Apr 16.
本文引用的文献
1
Enhanced Inflammasome Activity in Patients with Psoriasis Promotes Systemic Inflammation.银屑病患者的炎症小体活性增强可促进全身炎症。
J Invest Dermatol. 2021 Mar;141(3):586-595.e5. doi: 10.1016/j.jid.2020.07.012. Epub 2020 Sep 5.
2
Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1.激活的血小板通过 COX-1 诱导银屑病中的血管内皮细胞炎症反应。
Arterioscler Thromb Vasc Biol. 2020 May;40(5):1340-1351. doi: 10.1161/ATVBAHA.119.314008. Epub 2020 Mar 5.
3
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2019 ACC/AHA 心血管疾病一级预防指南：执行摘要：美国心脏病学会/美国心脏协会临床实践指南工作组的报告。
J Am Coll Cardiol. 2019 Sep 10;74(10):1376-1414. doi: 10.1016/j.jacc.2019.03.009. Epub 2019 Mar 17.
4
Inflammasome Signaling and Impaired Vascular Health in Psoriasis.银屑病中炎症小体信号与血管健康受损。
Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):787-798. doi: 10.1161/ATVBAHA.118.312246.
5
Safety and efficacy of statin therapy.他汀类药物治疗的安全性和有效性。
Nat Rev Cardiol. 2018 Dec;15(12):757-769. doi: 10.1038/s41569-018-0098-5.
6
The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis.对易患动脉粥样硬化者使用一级预防他汀类药物治疗。
Curr Atheroscler Rep. 2017 Oct 17;19(12):48. doi: 10.1007/s11883-017-0685-7.
7
Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis.他汀类降脂疗法在有和无银屑病患者中的有效性。
Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0.
8
Psoriasis.银屑病。
Nat Rev Dis Primers. 2016 Nov 24;2:16082. doi: 10.1038/nrdp.2016.82.
9
Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.银屑病患者中肿瘤坏死因子抑制剂治疗与心肌梗死风险之间的关联。
Arch Dermatol. 2012 Nov;148(11):1244-50. doi: 10.1001/archdermatol.2012.2502.
10
A guide to the design and analysis of small clinical studies.小型临床研究的设计与分析指南。
Pharm Stat. 2011 Jul-Aug;10(4):363-8. doi: 10.1002/pst.477. Epub 2010 Dec 8.
Zotero 插件